Summary:
- The article discusses the granting of Breakthrough Therapy Designation (BTD) by China's Center for Drug Evaluation (CDE) for Sunvozertinib, a drug developed by Apollomics for the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
- EGFR exon 20 insertion mutations are a rare and aggressive type of lung cancer that are difficult to treat, and Sunvozertinib is the first drug to receive BTD in China for this indication, indicating its potential as an important new treatment option.
- The BTD designation is expected to expedite the clinical development and regulatory review process for Sunvozertinib, potentially providing patients with this rare form of lung cancer access to a new targeted therapy.